| 非小细胞肺癌基因突变量与PD1单抗疗效关系的分析 |
| |
| 引用本文： | 齐晓光,祁春艳,王李杰,康馨丹,胡 毅.非小细胞肺癌基因突变量与PD1单抗疗效关系的分析[J].现代肿瘤医学,2018,0(19):3073-3076. |
| |
| 作者姓名： | 齐晓光 祁春艳 王李杰 康馨丹 胡 毅 |
| |
| 作者单位： | 1.解放军总医院肿瘤内科；2.国宾一科，北京 100853 |
| |
| 摘 要： | 目的:探索非小细胞肺癌基因突变量与PD1单抗疗效关系。方法:回顾性分析应用PD1单抗免疫治疗肿瘤患者，筛选其中非小细胞肺癌，入组患者须行基因突变检测，剔除其中合并EGFR、ALk等驱动基因突变患者；分析基因突变数量是否与免疫治疗疗效有关，同时分析对于是否带有基因突变，两组患者有效率、无进展生存等方面的差异。结果:对于非小细胞肺癌患者，是否带有非驱动基因突变，对于应用PD1单抗免疫治疗疗效，两组未见统计学差异，进一步分析显示，对于带有基因突变非小细胞肺癌患者，基因突变数量与PD1免疫治疗疗效关系，结果提示，多基因突变患者疗效（有效率50%）有优于单基因突变患者疗效（有效率29%）的趋势，但统计分析显示，多基因突变患者疗效并不优于单基因突变患者，且未见统计学差异（P=0.576）。结论:对于非小细胞肺癌患者，带有多基因突变患者的疗效有优于单基因突变患者疗效的趋势，或许更可能从免疫治疗中获益。但结果有待进一步多中心的临床研究证实。
|
| 关 键 词： | 非小细胞肺癌 基因突变量 PD1单抗 疗效 |
Study of the relationship between the gene mutation of non small cell lung cancer and the efficacy of PD1 monoclonal antibody |
| |
| Qi Xiaoguang,Qi Chunyan,Wang Lijie,Kang Xindan,Hu Yi.Study of the relationship between the gene mutation of non small cell lung cancer and the efficacy of PD1 monoclonal antibody[J].Journal of Modern Oncology,2018,0(19):3073-3076. |
| |
| Authors: | Qi Xiaoguang Qi Chunyan Wang Lijie Kang Xindan Hu Yi |
| |
| Affiliation: | 1.Department of Oncology；2.Department of Special Ward，Chinese PLA General Hospital，Beijing 100853，China. |
| |
| Abstract: | Objective:To explore the effect-relationship between gene mutation of non small cell lung cancer with PD1 monoclonal antibody effect.Methods:A retrospective analysis was conducted on lung cancer patients treated with PD1 monoclonal antibody.Thirty patients with lung adenocarcinoma were included in this study，the analysis of gene mutation must be detected in our study.Patients，who detected combining EGFR or/and ALk driven gene mutation，were excluded.Two groups(non-gene mutation group and gene mutation group)were divided.The difference of effect of immunotherapy and survival rate were valued and compared in the two groups.Results:Our study showed that in the patients of lung cancer with or without gene mutation，there was no difference in the effect of immunotherapy.Further more，the correlation between the number of gene mutation and the efficacy of PD1 immunotherapy was analyzed by survival analysis.Patients with muti-gene mutation had a more efficiency rate(50%)，compared with the single gene mutation group(29%).Conclusion:Compared with patients with single gene mutation，patients with muti-gene mutation Had a trend of the more efficiency，but the results need to be further confirmed by a multi-center clinical study.The quantitative gene mutation of lung cancer may be a potential predictor for selecting optimal patients to administrate PD1 immunotherapy. |
| |
| Keywords: | non small cell lung cancer gene mutation PD1 monoclonal antibody effective rate |
|
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
|
点击此处可从《现代肿瘤医学》下载全文 |
